• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关于针对 COVID-19 的临床试验中重要药物的简要综述。

A Short Review on Important Drugs Under Clinical Trial Against COVID-19.

机构信息

Resedential Area Apt. 4223, Indian Institute of Technology Jodhpur, Jodhpur 342037, India.

出版信息

Mini Rev Med Chem. 2021;21(13):1666-1678. doi: 10.2174/1389557521666201217145333.

DOI:10.2174/1389557521666201217145333
PMID:33334287
Abstract

Coronavirus spreads from one to another person, either by touching the hands or by touching the surface contaminated with this virus, and then touching the nose or mouth. COVID-19 infected human symptoms are like pneumonia symptoms, dry cough and high fever. Upper respiratory tract infections symptoms and sore throat are rare. It was first notified in China dated 12th December 2019 as a respiratory illness. In addition to travel restrictions and quarantine measures, everyone should follow the World Health Organization's advice guidelines on the management of humans infected with known or suspected infection with the SARS-CoV-2 virus at the personal level. The development of vaccine or medicines for the same is in progress and this short review will summarize the most potential candidates such as Remdesivir, Lopinavir and Ritonavir, Chloroquine, Hydroxychloroquine, Hydroxychloroquine with Azithromycin, Favipiravir, Umifenovir, and Ribavirin for its medicinal treatment.

摘要

冠状病毒通过接触被污染的手或表面,然后触摸鼻子或嘴巴传播给另一个人。COVID-19 感染人类的症状类似于肺炎症状,干咳和高烧。上呼吸道感染和喉咙痛的症状很少见。它于 2019 年 12 月 12 日在中国首次被通知为呼吸道疾病。除了旅行限制和检疫措施外,每个人都应该遵循世界卫生组织关于管理已知或疑似感染 SARS-CoV-2 病毒的个人建议指南。针对该病毒的疫苗和药物的研发正在进行中,这篇简短的综述将总结最有潜力的候选药物,如瑞德西韦、洛匹那韦和利托那韦、氯喹、羟氯喹、羟氯喹与阿奇霉素、法匹拉韦、乌米酚韦和利巴韦林。

相似文献

1
A Short Review on Important Drugs Under Clinical Trial Against COVID-19.关于针对 COVID-19 的临床试验中重要药物的简要综述。
Mini Rev Med Chem. 2021;21(13):1666-1678. doi: 10.2174/1389557521666201217145333.
2
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.SARS-CoV-2:洛匹那韦/利托那韦、达芦那韦/乌苯美司、羟氯喹、瑞德西韦、法匹拉韦等药物治疗新型冠状病毒的抗病毒治疗的最新报告。
Curr Med Chem. 2020;27(27):4536-4541. doi: 10.2174/0929867327666200416131117.
3
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.抗病毒联合治疗在新冠病毒感染有症状患者中的安全性和有效性 - 一项随机对照试验(SEV-COVID 试验):一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 20;21(1):866. doi: 10.1186/s13063-020-04774-5.
4
Impact of repurposed drugs on the symptomatic COVID-19 patients.重新利用药物对有症状的 COVID-19 患者的影响。
J Infect Public Health. 2021 Jan;14(1):24-38. doi: 10.1016/j.jiph.2020.11.009. Epub 2020 Dec 7.
5
An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine.冠状病毒 2(SARS-CoV-2)感染的抗病毒策略概述,特别提到抗疟药物氯喹和羟氯喹。
Int J Clin Pract. 2021 Mar;75(3):e13825. doi: 10.1111/ijcp.13825. Epub 2020 Nov 22.
6
Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment.抗病毒药物的组织分布会影响其在 COVID-19 治疗中降低病毒载量的能力。
Eur J Pharmacol. 2020 Dec 15;889:173634. doi: 10.1016/j.ejphar.2020.173634. Epub 2020 Oct 6.
7
Antiviral therapy for coronavirus disease 2019.2019冠状病毒病的抗病毒治疗
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 May 28;45(5):598-602. doi: 10.11817/j.issn.1672-7347.2020.200211.
8
A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2.抗病毒药物的比较分析:它们对 SARS-CoV-2 的疗效。
Int Immunopharmacol. 2021 Jan;90:107232. doi: 10.1016/j.intimp.2020.107232. Epub 2020 Nov 30.
9
Recent progress of antiviral therapy for coronavirus disease 2019.新型冠状病毒病抗病毒治疗的最新进展。
Eur J Pharmacol. 2021 Jan 5;890:173646. doi: 10.1016/j.ejphar.2020.173646. Epub 2020 Oct 24.
10
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.一项评估法匹拉韦和羟氯喹联合治疗中重度 COVID-19 住院成人的疗效和安全性的随机对照研究:研究方案的结构化总结。
Trials. 2020 Oct 31;21(1):904. doi: 10.1186/s13063-020-04825-x.

引用本文的文献

1
Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination.基于界面的 SARS-CoV-2 RNA 依赖性 RNA 聚合酶中与法匹拉韦结合位点的设计揭示了导致对链终止产生抗性的突变。
FEBS Lett. 2021 Sep;595(18):2366-2382. doi: 10.1002/1873-3468.14182. Epub 2021 Sep 1.